Several Superb Points On The Global Evolution Of Pharma Marketing
The recent landmark passage of health care reform legislation in the United States surely represents one of the most significant milestones in the global health industry and will certainly drive changes that will be far-reaching for all pharmaceutical companies and their marketing operations. We have seen many changes in the marketing landscape in most recent times, some have been to do with the lengthy economic retrenchment, yet they have all posted challenges for the pharmaceutical company and their supporting consultant. Traditional methods of operation simply do not work anymore and organisations have been forced to become more consumer-centric and strategically positioned in order for their voices to be heard in the marketplace.
The United States legislation could be viewed, on the one hand, as being a potential boon for pharmaceutical companies, as upwards of 30 million people could be expected to be brought into the insurance coverage arena, with consequent potential for enhanced sales. On the other hand, many new pieces of legislation will lead to different procedures and the establishment of new standards, forcing the very make-up of the market in the US to change out of all recognition, challenging budgets like never before. It is simply too early to tell what the new market will look like.
A vast new market will now open as these end-users come into the picture and it will be necessary to team up with new methods of information deployment accordingly. Pharmaceutical marketing methods are having to come to terms with the new digital communication age, opening online channels that were simply not there before, as healthcare providers use these channels to communicate with their patients and clients.
As information is disseminated online, consumers may in increasing numbers be driven by social media and word of mouth stimuli and healthcare providers may find that they have to rework their positions, as those who recommend products to the final marketplace. Not surprisingly, techniques and approaches will need to be continuously modified, so that the company’s message is not diluted or delivered in an inefficient manner, within this new and evolving communications framework.
It’s likely that there will be a shift towards prevention and health awareness and that more funds will be allocated from a global perspective towards this facet of education and the dissemination of products and services accordingly. In terms of its role as a good corporate citizen, the pharmaceutical company will now need to be seen as much as anything else as an educator and a role model in preaching and promoting good health care practices. When it comes to funding, it also remains to be seen how the restructured healthcare arena will cope with its repositioned funding sources, restructured insurance markets and new consumer integration. New accounts will be defined in different ways and therefore , as part of an overall field, will be even more critical.
There is little doubt that, as the United States healthcare industry is completely reinvented, changes will impact the pharmaceutical marketing business all around. Change is the byword as the entire business repositions and escapes from recession, with the new digital communication methodology completely rewriting the marketing rules, as we attempt to bring the correct message to the end-user.
Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.
